Gn-RH agonist zoladex (goserelin acetate), the first peptide-based antitumor drug approved by the Food and Drug Administration (FDA), decreases U-373MG/U-87MG/LN229 glioblastoma cell proliferation and increases kininogen 1 expression [85]. The gene discussed is GNRH1; the disease is glioblastoma.